APTARGROUP $57.34

up +0.20


18/6/2013 04:18 PM  |  NYSE : ATR  |  Industries : Manufacturing / Plastics Product Manufacturing
Last Trade: 57.34
Trade Time: Jun 18 4:01 PM Eastern Daylight Time
Change: 0.20 (0.35 %)
Prev Close: 57.14
Open: 57.20
Bid: 57.06
Ask: 57.62
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
Get Trend Analysis Icon Get ATR Trend Analysis - it has underperformed the S&P 500 by 14%

ETF Alternatives



People viewing ATR also viewed: , , , ,

Competitors

Ticker Name Volume % Change
STRI STR HOLDINGS 95.2K +0.02%
CXDC CHINA XD PLASTICS CO. 16.6K +0.02%
AEPI AEP INDUSTRIES 38.5K +0.02%
MYE MYERS INDUSTRIES 103.6K +0.01%
AWI ARMSTRONG WORLD INDSTRIES 280.3K +0.01%

Insider Transactions

Date Name Title Volume Trade Price Holding Change
5/24/2013 Kampouri Monnas Giovanna Director -5,776 $56.10 -72.20%
5/16/2013 Kuhn Robert EVP & CFO -13,000 $56.77 -68.57%
5/16/2013 Kuhn Robert EVP & CFO 13,000 $37.52 218.16%
5/13/2013 HAGGE STEPHEN J President and CEO 35,000 $20.06 66.49%
5/13/2013 HAGGE STEPHEN J President and CEO -35,000 $56.12 -39.94%
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (ATR), click here.
View All

ATR Stock Analysis

  1. Alliant Inks Deal with Rolls-Royce - Analyst Blog

    (ATRO,ATK,CW,KTOS )
    Alliant Techsystems Inc. enters into a contract, worth over $50 million, with United Kingdom-based Rolls-Royce plc.
  2.

    Positive Data for COV's Solitaire - Analyst Blog

    (SYK,COV,HAE,ATRC )
    Covidien presented encouraging data at the 2013 ESC regarding the superiority of its Solitaire FR device for acute ischemic stroke treatment.
  3.

    Abbott Progresses with Absorb in Japan - Analyst Blog

    (ABT,ABBV,BAXS,ATRC )
    Abbott Labs (ABT) recently announced that it has initiated a randomized controlled study in Japan to evaluate Absorb, its bioresorbable vascular scaffold (BVS) device, in patients suffering from coronary artery disease (CAD).

  4. FDA Nod for STJ's Ellipse & Assura - Analyst Blog

    (STJ,BAXS,HAE,ATRC )
    St. Jude has won the U.S. FDA approval for its Ellipse and SJM Assura portfolio of ICDs and CRT-Ds.
  5.

    Symmetry Provides Dismal 2013 View - Analyst Blog

    (SMA,HAE,BAXS,ATRC )
    Symmetry has revised its guidance for 2013 based on the company's disappointing first-quarter results as well as a tempered forecast for the rest of the year.
  6.

    Broad Weakness Makes It Harder To Like St. Jude Today

    (STJ,BSX,MDT,EW,JNJ,ATRC )
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock to own for a little while yet.
Free Reports
  1.

    7 Proven Strategies for Market-Stomping Stocks

    Discover Investing Strategies that will Benefit Every Investor Today!
  2.

    Forbes Quant Model: 3 Top Stocks

    Using Forbes’ exclusive Quant Model, we’ve chosen three stocks that we think could double in price in the next 12 months.
  3.

    3 Stocks Peter Lynch Would Buy Today

    This new special report identifies 3 stocks based on Lynch’s market-trouncing strategy that could more than double in the next 12 months.
Marketplace
Trading Center